. Cis-2-phenyl-2-cyclohexyl-r-5 [(dimethylamino)-methyl]-1,3-oxathiolane cis [(±)1] and trans [(±)2] 3-oxide methiodides together with the enantiomers (+)2 and (-)2 where evaluated for their antimuscarinic activity in functional (in vivo and in vitro) and in binding studies. The results indicate that in all the receptor subtypes the trans isomer (±)2 is more active than the cis one (±)1. Of the two enantiomers, (+)2 displays the highest affinity while the values of eudismic ratios, although large, are similar for all the subtypes. Furthermore, the tested oxathiolanes show a small degree of selectivity in binding studies while in functional studies selectivity is absent.
Pharmacological Characterization of Chiral Muscarinic Antagonists cis-2-Phenyl-2-cyclohexyl-r-5-[(dimethylamino)-methyl]1,3-oxathiolane-3-oxide Methiodide / Angeli, P.; Balduini, W.; Brasili, Livio; Cantalamessa, F.; Cattabeni, F.; Marucci, G.. - In: PHARMACEUTICAL AND PHARMACOLOGICAL LETTERS. - ISSN 0939-9488. - STAMPA. - 1:(1992), pp. 111-114.
Pharmacological Characterization of Chiral Muscarinic Antagonists cis-2-Phenyl-2-cyclohexyl-r-5-[(dimethylamino)-methyl]1,3-oxathiolane-3-oxide Methiodide
BRASILI, Livio;
1992
Abstract
. Cis-2-phenyl-2-cyclohexyl-r-5 [(dimethylamino)-methyl]-1,3-oxathiolane cis [(±)1] and trans [(±)2] 3-oxide methiodides together with the enantiomers (+)2 and (-)2 where evaluated for their antimuscarinic activity in functional (in vivo and in vitro) and in binding studies. The results indicate that in all the receptor subtypes the trans isomer (±)2 is more active than the cis one (±)1. Of the two enantiomers, (+)2 displays the highest affinity while the values of eudismic ratios, although large, are similar for all the subtypes. Furthermore, the tested oxathiolanes show a small degree of selectivity in binding studies while in functional studies selectivity is absent.Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris